Varenicline and Nicotine Replacement Use Associated With US Food and Drug Administration Drug Safety Communications

Key Points Question Did use of varenicline change after early US Food and Drug Administration drug safety communications regarding neuropsychiatric adverse events? Findings This cross-sectional study observed a reduction in varenicline prescribing following the release of US Food and Drug Administration drug safety communications on the medication. Interrupted time series analysis showed a 68.7% decrease in Veterans Health Administration outpatient prescriptions and a 38.0% decrease in Medicaid prescriptions. Meaning In the wake of US Food and Drug Administration and Veterans Health Administration communications, prescriptions for varenicline decreased significantly, which may have been associated with negative public health consequences.

• Publication year

  2019

• Venue

  JAMA Network Open

• Publication date

  2019-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamanetworkopen.2019.10626PMID 31483473PMCID 6754175
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Office

  2021cited by this paper
• The effects of prescribing varenicline on two‐year health outcomes: an observational cohort study using electronic medical records

  2018cited by this paper
• Healthcare Costs of Smokers Using Varenicline Versus Nicotine-Replacement Therapy Patch in the United States: Evidence from Real-World Practice

  2018cited by this paper
• Trends in utilization of smoking cessation agents before and after the passage of FDA boxed warning in the United States.

  2017cited by this paper
• (2017). The Food and Drug Administration and varenicline: should Risk Communication Be Improved? Addiction

  2017cited by this paper
• Comparing Adoption of Breakthrough and “Me-too” Drugs Among Medicare Beneficiaries: a Case Study of Dipeptidyl Peptidase-4 Inhibitors

  2017cited by this paper
• The effectiveness of varenicline versus nicotine replacement therapy on long-term smoking cessation in primary care: a prospective cohort study of electronic medical records

  2017cited by this paper
• The Food and Drug Administration and varenicline: should risk communication be improved?

  2016cited by this paper
• Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.

  2016cited by this paper
• A comparison of neuropsychiatric adverse events during early treatment with varenicline or a nicotine patch.

  2016cited by this paper
• National antidepressant prescribing in children and adolescents with mental health disorders after an FDA boxed warning.

  2014cited by this paper
• Number of Patients Studied Prior to Approval of New Medicines: A Database Analysis

  2013cited by this paper
• Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

  2013cited by this paper
• Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors: A Systematic Review

  2012cited by this paper
• STROBE Statement - Checklist of items that should be included in reports of cross-sectional studies

  2011cited by this paper
• Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial.

  2010cited by this paper
• Decreased Use of Antidepressants in Youth After US Food and Drug Administration Black Box Warning.

  2009cited by this paper
• A framework for tobacco control: lessons learnt from Veterans Health Administration

  2008cited by this paper
• Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents.

  2007cited by this paper
• STROBE Statement – checklist of items that should be included in reports of observational studies1 (© STROBE Initiative)

  2007cited by this paper
• The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality

  2005cited by this paper
• The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality

  2005cited by this paper

• How does DRG reform affect length of stay and hospitalization costs in traditional Chinese medicine hospitals?-an empirical analysis using interrupted time-series model from two cities in western China.

  2026cites this paper
• Method development and validation of varenicline in plasma samples of patients under smoking cessation treatment

  2024cites this paper
• Postmarket safety communications on drugs approved in Japan: A 25‐year analysis

  2024cites this paper
• Access and Safety-The FDA Drug Approval Conundrum.

  2024cites this paper
• Trends in Over-the-Counter Nicotine Replacement Therapy Sales, U.S., 2017‒2020.

  2023cites this paper
• Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System

  2023cites this paper
• Factors impeding psychiatrists from promoting smoking cessation among people with serious mental illness – A mixed methods study

  2022cites this paper
• Varenicline (Chantix): The Smoking Cessation Medication Prescribers May Be Avoiding

  2022cites this paper
• Characterising the use of varenicline: an analysis of the Australian dispensing claims data

  2022cites this paper
• Trends in Incident Varenicline Prescribing Among Veterans Following the US Food and Drug Administration Drug Safety Warnings.

  2021cites this paper
• Adherence to smoking cessation guidelines (5As) by psychiatrists and primary care physicians for persons with serious mental illness

  2021cites this paper
• Receipt of and Spending on Cessation Medication Among US Adults With Employer-Sponsored Health Insurance, 2010 and 2017

  2021cites this paper
• Gadolinium Concentrations in Biological Matrices From Patients Exposed to Gadolinium-Based Contrast Agents

  2021cites this paper
• Risk of neuropsychiatric adverse events associated with varenicline treatment for smoking cessation among Dutch population: A sequence symmetry analysis

  2021cites this paper
• Looking Back and Going Forward: Roles of Varenicline and Electronic Cigarettes in Smoking Cessation

  2021cites this paper
• Cigarette Smoking and Heavy Alcohol Drinking: The Challenges and Opportunities for Combination Treatments.

  2021cites this paper
• Comparison of smoking cessation program registration, participation, smoking cessation medication utilization and abstinence rates between smokers with and without schizophrenia, schizo-affective disorder or bipolar disorder.

  2021cites this paper
• Comparison of Perceptions and Smoking Cessation Experiences Between Smokers With and Without Serious Mental Illness in a Large Health Maintenance Organization

  2021cites this paper
• Information shocks and pharmaceutical firms' marketing efforts: Evidence from the Chantix black box warning removal.

  2021cites this paper
• Effectiveness and safety of medicines used in COPD patients

  2020cites this paper
• Medikamente zur Behandlung von Abhängigkeitserkrankungen und abhängigem Verhalten

  2020cites this paper
• Agents for Treatment of Withdrawal and Dependency: Varenicline

  2020cites this paper
• Suicide Attempt in a 38-Year-Old Patient on Varenicline While Intoxicated With Alcohol

  2020cites this paper
• Navel to Knees With Chlorhexidine Gluconate: Preventing Catheter-Associated Urinary Tract Infections.

  2019cites this paper